Company profile: Artbio
1.1 - Company Overview
Company description
- Provider of clinical-stage alpha radioligand medicines and enabling technologies, including AB001, a 212Pb-based radiopharmaceutical candidate for prostate cancer in Phase I/II trials; AlphaDirect technology for isolating Pb-212 to enable distributed manufacturing; and a distributed end-to-end manufacturing network to deliver therapeutic candidates rapidly and flexibly.
Products and services
- AlphaDirect Technology: Proprietary system that isolates Pb-212 to enable distributed manufacturing of alpha radioligand therapies, supporting decentralized production and patient access
- AB001: 212Pb-based radiopharmaceutical candidate for treating prostate cancer, currently in Phase I and II clinical trials within ARTBIO’s development pipeline
- Distributed Manufacturing Network: End-to-end manufacturing network engineered to deliver ARTBIO’s therapeutic candidates rapidly and flexibly to patients by coordinating distributed production
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Artbio
Synta Pharmaceuticals
HQ: United States
Website
- Description: Provider of small molecule therapeutics to treat cancer and chronic inflammatory diseases, focused on the development and commercialization of these drugs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Synta Pharmaceuticals company profile →
Ernexa
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical research and development of cytokine-based therapies, using mRNA to express reprogramming proteins for allogeneic pluripotent stem cell-derived CAR-T and CAR-NK therapies and to express gene-editing proteins, including UltraSlice, to deactivate, repair, insert, replace, or delete specific DNA sequences, and employing LNP technology, such as ToRNAdo, for efficient and safe delivery of mRNA cargo into human cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ernexa company profile →
HistoGeneX
HQ: Belgium
Website
- Description: Provider of biomarker technologies for translational and clinical research via CAP, CLIA, and BELAC-accredited laboratories. Offers integrated sample management and logistics, biomarker strategy support, oncology assays; flow cytometry, histopathology, genomics, immunoassays; plus CellEngine cytometry analysis software and Olink PEA protein biomarker quantification.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full HistoGeneX company profile →
MDNA Life Sciences
HQ: United States
Website
- Description: Provider of proprietary, blood-based diagnostic tests leveraging mitochondrial DNA to improve early disease detection, diagnosis, treatment, prognosis and monitoring. Offerings include the Mitomic Prostate Test (3.4 kb deletion to assess significant prostate cancer risk and aid biopsy decisions) and Mitomic Endometriosis Test (8.7 kb deletion to reduce diagnostic delays), powered by Mitomic Technology to detect disease-specific mtDNA biomarkers with high sensitivity and specificity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MDNA Life Sciences company profile →
Loxo Oncology
HQ: United States
Website
- Description: Provider of targeted cancer therapies for genetically defined patient populations, focused on developing biopharmaceutical treatments and rapidly advancing them into the clinic to achieve outsized clinical effects.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Loxo Oncology company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Artbio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Artbio
2.2 - Growth funds investing in similar companies to Artbio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Artbio
4.2 - Public trading comparable groups for Artbio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →